Fintech

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Globenewswire·April 2, 2026 at 11:30 AM

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

DOJ crypto memo author named interim AG
CoinDesk
Drift crypto exchange remains frozen after attack
PYMNTS
Amazon adds fuel surcharge for sellers
PYMNTS
DOJ Appeals Anthropic AI Ban Restoration
PYMNTS

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

DOJ crypto memo author named interim AG

Drift crypto exchange remains frozen after attack

Amazon adds fuel surcharge for sellers

DOJ Appeals Anthropic AI Ban Restoration